Cholesterol Treatment Decisions: Recent Updates to Guidelines and St…

Gary Martin

Can I Ever Be Cured? Strategies for Remission of Type 2 Diabetes

Keck School of Medicine of USC

R. Retnakaran

Should I Use a Continuous Glucose Monitor, Even if I'm Healthy?

Integrative Medicine - Astrid Pujari

A. Pujari

The 'Familial' in Familial Hypercholesterolemia

Samuel Gidding

FLOW Trial Results: GLPs, the Kidneys, and Even More to Come!!

Robert Busch

Year in Review - Obesity and Cardiovascular Kidney Syndrome: New Goa…

Samina Yunus

The Cardiometabolic Syndrome: A New Framework for Understanding Hear…

San Diego Heart Failure Symposiums

P. Taub

Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists

Ezekiel Emanuel

Weight Loss and Pharmacologic Management of Obesity in 2024

Caroline Apovian

The Case for Coronary Artery Calcium Scoring for Personalized Preven…

Todd Villines

Functional Hypothalamic Amenorrhea: Consequences Beyond the Menstrua…

Heart in Diabetes (HiD)

C. Shufelt

GLP-1 in Obesity Treatment

Ethan Lazarus

Obesity in the Year 2024

Barbara Mcgowan

CT Guided Treatment of Coronary Artery Disease: A Step Towards Preci…

Amir Ahmadi

Tirzepatide for OSA

Atul Malhotra

Nutrition Advice for Patients on GLPs for Obesity

Dr. Carolynn Francavilla

C. Francavilla Brown

Cardiovascular Disease in the Very Old

Heart in Diabetes (HiD)

C. Ballantyne

What Are the Metabolic Consequences of Insulin Resistance and What I…

Penn Medicine Heart and Vascular Center

D. Soffer

Semaglutide 2.4 mg Efficacy and Safety in People with Obesity and Kn…

Henning Bliddal

Glucagon-like Peptide-1 Receptor Agonist-Based Agents and Weight Los…

Robert Dubin